05 August 2021: Database Analysis
N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer
Yanni Song 12BCEFG , Chaojing Zheng 3C , Yangbao Tao 3D , Rui Huang 3E , Qian Zhang 4AE*DOI: 10.12659/MSM.929615
Med Sci Monit 2021; 27:e929615
Supplementary Table 1 Expression of N6-methyladenosine regulators in different cellularity, tumor stage, or Nottingham prognostic index groups.
| m6A regulators | Cellularity | NPI Class | Tumor stage | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| High | Moderate | Low | ≤2.4 | 2.4–3.4 | 3.4–5.4 | ≥5.5 | 1 | 2 | 3 | |
| METTL3 (mean (SD)) | 8.30 (0.40) | 8.27 (0.39) | 8.34 (0.39) | 8.32 (0.36) | 8.34 (0.38) | 8.28 (0.41) | 8.25 (0.40) | 8.34 (0.39) | 8.27 (0.40) | 8.28 (0.40) |
| METTL14 (mean (SD)) | 6.08 (0.24) | 6.06 (0.23) | 6.03 (0.23) | 6.07 (0.23) | 6.07 (0.21) | 6.06 (0.24) | 6.02 (0.26) | 6.05 (0.22) | 6.06 (0.24) | 6.05 (0.26) |
| METTL16 (mean (SD)) | 6.63 (0.33) | 6.68 (0.33) | 6.66 (0.32) | 6.72 (0.32) | 6.68 (0.31) | 6.63 (0.34) | 6.58 (0.31) | 6.64 (0.31) | 6.64 (0.33) | 6.56 (0.29) |
| RBM15 (mean (SD)) | 8.21 (0.42) | 8.13 (0.43) | 8.05 (0.39) | 8.03 (0.43) | 8.07 (0.38) | 8.21 (0.43) | 8.24 (0.44) | 8.11 (0.39) | 8.15 (0.44) | 8.20 (0.44) |
| WTAP (mean (SD)) | 7.01 (0.59) | 6.98 (0.56) | 7.13 (0.52) | 7.04 (0.59) | 6.94 (0.54) | 7.04 (0.58) | 7.06 (0.60) | 7.07 (0.59) | 7.02 (0.59) | 7.12 (0.61) |
| KIAA1429 (mean (SD)) | 8.07 (0.55) | 8.03 (0.55) | 7.88 (0.44) | 7.95 (0.56) | 8.02 (0.56) | 8.05 (0.53) | 8.01 (0.52) | 8.00 (0.55) | 8.01 (0.52) | 8.01 (0.50) |
| RBM15B (mean (SD)) | 6.55 (0.40) | 6.50 (0.36) | 6.49 (0.35) | 6.58 (0.33) | 6.62 (0.36) | 6.49 (0.38) | 6.44 (0.39) | 6.56 (0.36) | 6.49 (0.39) | 6.45 (0.37) |
| ALKBH5 (mean (SD)) | 11.23 (0.38) | 11.22 (0.38) | 11.27 (0.33) | 11.30 (0.35) | 11.26 (0.36) | 11.21 (0.36) | 11.21 (0.47) | 11.24 (0.36) | 11.22 (0.38) | 11.17 (0.41) |
| EIF3 (mean (SD)) | 8.88 (0.79) | 8.79 (0.77) | 8.59 (0.84) | 8.47 (0.79) | 8.75 (0.78) | 8.84 (0.79) | 9.04 (0.82) | 8.62 (0.80) | 8.84 (0.81) | 8.91 (0.83) |
| YTHDF1 (mean (SD)) | 9.35 (0.45) | 9.29 (0.41) | 9.25 (0.39) | 9.20 (0.39) | 9.28 (0.42) | 9.32 (0.44) | 9.41 (0.40) | 9.23 (0.42) | 9.31 (0.44) | 9.34 (0.41) |
| ZC3H13 (mean (SD)) | 5.23 (0.13) | 5.24 (0.13) | 5.23 (0.12) | 5.24 (0.13) | 5.24 (0.13) | 5.23 (0.13) | 5.24 (0.13) | 5.24 (0.13) | 5.23 (0.14) | 5.22 (0.13) |
| YTHDC1 (mean (SD)) | 6.08 (0.32) | 6.04 (0.29) | 5.96 (0.26) | 6.06 (0.34) | 6.05 (0.30) | 6.04 (0.30) | 6.05 (0.30) | 6.01 (0.30) | 6.07 (0.30) | 6.01 (0.27) |
| YTHDF3 (mean (SD)) | 7.29 (0.40) | 7.19 (0.37) | 7.15 (0.34) | 7.12 (0.40) | 7.17 (0.35) | 7.27 (0.39) | 7.28 (0.42) | 7.22 (0.38) | 7.24 (0.39) | 7.30 (0.36) |
| HNRNPA2B1 (mean (SD)) | 8.45 (0.62) | 8.47 (0.62) | 8.46 (0.55) | 8.52 (0.52) | 8.50 (0.58) | 8.45 (0.64) | 8.43 (0.58) | 8.50 (0.57) | 8.47 (0.60) | 8.45 (0.58) |
| YTHDC2 (mean (SD)) | 6.23 (0.31) | 6.22 (0.29) | 6.22 (0.24) | 6.27 (0.28) | 6.30 (0.26) | 6.20 (0.30) | 6.14 (0.29) | 6.21 (0.29) | 6.22 (0.30) | 6.14 (0.31) |
| YTHDF2 (mean (SD)) | 8.77 (0.40) | 8.70 (0.38) | 8.75 (0.36) | 8.75 (0.42) | 8.72 (0.37) | 8.75 (0.39) | 8.76 (0.38) | 8.76 (0.36) | 8.75 (0.40) | 8.74 (0.34) |
| CBLL1 (mean (SD)) | 7.56 (0.36) | 7.50 (0.33) | 7.53 (0.29) | 7.49 (0.29) | 7.48 (0.32) | 7.55 (0.35) | 7.59 (0.35) | 7.55 (0.32) | 7.52 (0.35) | 7.63 (0.34) |
| IGF2BP2 (mean (SD)) | 6.89 (0.84) | 6.84 (0.70) | 7.02 (0.72) | 6.72 (0.53) | 6.73 (0.53) | 6.97 (0.86) | 6.93 (0.84) | 6.81 (0.68) | 6.89 (0.78) | 6.94 (0.86) |
| IGF2BP1 (mean (SD)) | 5.60 (0.21) | 5.59 (0.20) | 5.58 (0.20) | 5.57 (0.20) | 5.59 (0.21) | 5.59 (0.20) | 5.61 (0.22) | 5.57 (0.19) | 5.61 (0.21) | 5.62 (0.22) |
| IGF2BP3 (mean (SD)) | 5.81 (0.74) | 5.71 (0.52) | 5.80 (0.64) | 5.58 (0.24) | 5.60 (0.36) | 5.86 (0.76) | 5.86 (0.64) | 5.73 (0.51) | 5.78 (0.68) | 5.91 (0.78) |
| mA – N6-methyladenosine; NPI – Nottingham prognostic index; SD – standard deviation. | ||||||||||